The Relationship between Plasma Pentraxin 3 and Serum Amyloid P Levels and Disease Activity in Ankylosing Spondylitis

Özdemirel, Ali Erhan; Güven, Serdar Can; Sunar, İsmihan; Sürmeli, Zühre Sarı; Doğancı, Alper; Tutkak, Hüseyin; Ataman, Şebnem

doi:10.1155/2022/7243399

Cited by 6 publications

(4 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…PTX-3 levels were also not correlated with disease activity. Although there are few studies in the literature examining PTX-3 levels and disease activity, to the best of our knowledge, this is the first study to compare PTX-3 with serum IL-17 and IL-23 levels, as well as nr-AxSpA and r-AxSpA groups [14][15][16].…”

Section: Axspa (N = 50)mentioning

confidence: 99%

See 1 more Smart Citation

Is the Level of Pentraxin-3 a Valid Biomarker in Axial Spondyloarthritis?

Oruçoğlu

Balci-Fidanci

Tamer

2023

Aktuelle Rheumatologie

View full text Add to dashboard Cite

Background Pentraxin-3 (PTX-3) is essential in inflammation, remodelling and regulation of inflammation in various rheumatic diseases. This study aimed to determine whether serum PTX-3 levels indicate increased inflammation and disease activity in patients with axial spondyloarthritis (AxSpA). Material and Methods The study comprised 50 AxSpA patients and 20 healthy controls (HC). Serum PTX-3, interleukin (IL)-17 and IL-23 levels were compared between AxSpA patients and the control group. The relationship between PTX-3 levels and acute-phase reactants and disease activity was examined. Disease activity was scored using the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) and the Ankylosing Spondylitis Disease Activity Score-CRP (ASDAS-CRP). Patients with AxSpA were also separated into two subgroups – non-radiographic AxSpA (nr-AxSpA) and radiographic AxSpA (r-AxSpA) – and compared based on their PTX-3 levels. PTX-3, IL-17 and IL-23 levels were measured using the enzyme-linked immunosorbent assay method. Results PTX-3 levels were higher in patients with AxSpA compared with the HC (2.69±2.03 vs 1.84±1.03 ng/mL, p=0.025). When patients were divided into nr-AxSpA and r-AxSpA subgroups, this difference was found to be only due to patients with r-AxSpA. The r-AxSpA group had significantly higher PTX-3 levels than the nr-AxSpA and HC groups (p=0.020 and p=0.016, respectively). There was no statistically significant difference in PTX-3 levels between the nr-AxSpA and HC groups (p=0.961). There was no correlation between PTX-3 levels and acute-phase reactants, IL-17, IL-23 and disease activity scores (BASDAI and ASDAS-CRP). Conclusion These findings support the hypothesis that PTX-3 levels are higher in patients with r-AxSpA, where chronic inflammation and structural progression are more pronounced and can be used as an inflammation marker. However, they demonstrate that this relationship does not exist in nr-AxSpA and that there is no correlation between disease activity and PTX-3 levels. Thus, PTX-3 levels may be associated with structural changes.

show abstract

Section: Axspa (N = 50)mentioning

confidence: 99%

“…Ozdemirel et al [15] examined plasma PTX-3 and serum amyloid P (SAP) levels in 100 AS patients and reported that AS patients had higher PTX-3 and SAP levels than the healthy group. Similar to our study, they found no correlation between PTX-3 levels and disease activity.…”

Section: Axspa (N = 50)mentioning

confidence: 99%

Is the Level of Pentraxin-3 a Valid Biomarker in Axial Spondyloarthritis?

Oruçoğlu

Balci-Fidanci

Tamer

2023

Aktuelle Rheumatologie

View full text Add to dashboard Cite

show abstract

“…Pentraxin 3 is a long pentraxin overexpressed during the acute-phase response, playing significant roles in the innate immune response and inflammation, as well as in tissue damage and remodeling. Its direct implications in axSpA and many other rheumatic disorders have been extensively studied [ 77 ]; unfortunately, some studies have shown no association with disease activity and acute inflammation in axSpA [ 56 , 78 ].…”

Section: Systemic Markers Of Inflammationmentioning

confidence: 99%

Practical Significance of Biomarkers in Axial Spondyloarthritis: Updates on Diagnosis, Disease Activity, and Prognosis

Diaconu

Ceasovschih

Șorodoc

et al. 2022

IJMS

View full text Add to dashboard Cite

Axial spondyloarthritis (axSpA) is a chronic inflammatory disease that can lead to ankylosis by secondary ossification of inflammatory lesions, with progressive disability and a significant impact on quality of life. It is also a risk factor for the occurrence of comorbidities, especially cardiovascular diseases (CVDs), mood disorders, osteoporosis, and malignancies. Early diagnosis and treatment are needed to prevent or decrease functional decline and to improve the patient’s prognosis. In respect of axSpA, there is an unmet need for biomarkers that can help to diagnose the disease, define disease activity and prognosis, and establish personalized treatment approaches. The aim of this review was to summarize the available information regarding the most promising biomarkers for axSpA. We classified and identified six core categories of biomarkers: (i) systemic markers of inflammation; (ii) molecules involved in bone homeostasis; (iii) HLA-B27 and newer genetic biomarkers; (iv) antibody-based biomarkers; (v) microbiome biomarkers; and (vi) miscellaneous biomarkers. Unfortunately, despite efforts to validate new biomarkers, few of them are used in clinical practice; however, we believe that these studies provide useful data that could aid in better disease management.

show abstract

“…In AS patients, the inflammatory response is often accompanied by aberrant production of multiple cytokines. For example, tumour necrosis factor-alpha (TNFa), interleukin-1 beta (IL-1b) and interleukin-17 .Such irregular production and activation of these inflammatory factors can lead to joint and spinal inflammation, pain and tissue damage (5)(6)(7). Therapeutic approaches targeting these inflammatory factors, such as the use of biological agents to inhibit TNFa, have gained widespread acceptance in the treatment of AS (8).…”

Section: Introductionmentioning

confidence: 99%

Exploring causal correlations between inflammatory cytokines and ankylosing spondylitis: a bidirectional mendelian-randomization study

Fang,

Liu,

Qiu

et al. 2023

Front. Immunol.

View full text Add to dashboard Cite

BackgroundThe impact of inflammatory factors on the development of Ankylosing Spondylitis (AS) is widely recognized, but the exact causal relationship remains unclear.MethodsThe bidirectional mendelian-randomization study utilized genetic data from a genome-wide association study (GWAS) of 186 AS cases and 456,162 controls of European ancestry. Inflammatory cytokines were obtained from a GWAS summary of 8,293 healthy participants. Causal associations were primarily investigated using the inverse variance-weighted method, supplemented by MR Egger, weighted median and weighted mode analyses. Heterogeneity in the results was assessed using the Cochrane Q test. Horizontal pleiotropy was evaluated through the MR-Egger intercept test and the MR pleiotropy residual sum and outliers (MR-PRESSO) test. Sensitivity analysis was conducted through leave-one-out analysis.ResultsThe results suggest a genetically predicted potential association between beta-nerve growth factor (βNGF), Interleukin-1-beta (IL-1β), and TNF-related apoptosis inducing ligand (TRAIL) with the risk of AS (OR: 2.17, 95% CI: 1.13-4.16; OR: 0.41, 95% CI: 0.18-0.95,; OR: 1.47, 95% CI: 1.02-2.13).Additionally, Interleukin-12p70 (IL-12p70), Interleukin-17 (IL-17), Interleukin-6 (IL-6), Interleukin-4 (IL-4), Stromal-cell-derived factor 1 alpha (SDF−1α), Macrophage inflammatory protein 1β (MIP1β), Monocyte chemoattractant protein-3 (MCP-3), Platelet-derived growth factor bb (PDGFbb), Granulocyte-colony stimulating factor (GCSF), Fibroblast growth factor basic (bFGF), TNF-related apoptosis inducing ligand (TRAIL), and Interferon-gamma (IFN -γ) are suggested as consequences of AS in genetically prediction.No evidence of horizontal pleiotropy or heterogeneity between the genetic variants was found (P>0.05), and a leave-one-out test confirmed the stability and robustness of this association.ConclusionThese findings suggest that βNGF, IL-1β, and TRAIL may play a crucial role in the pathogenesis of AS. Additionally, AS may impact the expression of cytokines such as IL-12p70, IL-17, IL-6, IL-4, SDF−1α, MIP1β, MCP-3, PDGFbb,GCSF, bFGF,TRAIL,and IFN-γ. Further investigations are warranted to determine whether these biomarkers can be utilized for the prevention or treatment of AS.

show abstract

The Relationship between Plasma Pentraxin 3 and Serum Amyloid P Levels and Disease Activity in Ankylosing Spondylitis

Cited by 6 publications

References 17 publications

Is the Level of Pentraxin-3 a Valid Biomarker in Axial Spondyloarthritis?

Is the Level of Pentraxin-3 a Valid Biomarker in Axial Spondyloarthritis?

Practical Significance of Biomarkers in Axial Spondyloarthritis: Updates on Diagnosis, Disease Activity, and Prognosis

Exploring causal correlations between inflammatory cytokines and ankylosing spondylitis: a bidirectional mendelian-randomization study

Contact Info

Product

Resources

About